Study of the Safety, Tolerability and Pharmacokinetics of LY3016859 After Single Intravenous and Subcutaneous Dosing in Healthy Volunteers

Trial Profile

Study of the Safety, Tolerability and Pharmacokinetics of LY3016859 After Single Intravenous and Subcutaneous Dosing in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jun 2014

At a glance

  • Drugs LY 3016859 (Primary) ; LY 3016859 (Primary)
  • Indications Diabetic nephropathies
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 13 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top